Breast Cancer Subtype by Imbalanced Omics Data through A Deep Learning Fusion Model

Author(s):  
Jingwen Zeng ◽  
Hongmin Cai ◽  
Tatsuya Akutsu
2020 ◽  
Vol 47 (9) ◽  
pp. 835-841
Author(s):  
Joungmin Choi ◽  
Jiyoung Lee ◽  
Jieun Kim ◽  
Jihyun Kim ◽  
Heejoon Chae

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2013
Author(s):  
Edian F. Franco ◽  
Pratip Rana ◽  
Aline Cruz ◽  
Víctor V. Calderón ◽  
Vasco Azevedo ◽  
...  

A heterogeneous disease such as cancer is activated through multiple pathways and different perturbations. Depending upon the activated pathway(s), the survival of the patients varies significantly and shows different efficacy to various drugs. Therefore, cancer subtype detection using genomics level data is a significant research problem. Subtype detection is often a complex problem, and in most cases, needs multi-omics data fusion to achieve accurate subtyping. Different data fusion and subtyping approaches have been proposed over the years, such as kernel-based fusion, matrix factorization, and deep learning autoencoders. In this paper, we compared the performance of different deep learning autoencoders for cancer subtype detection. We performed cancer subtype detection on four different cancer types from The Cancer Genome Atlas (TCGA) datasets using four autoencoder implementations. We also predicted the optimal number of subtypes in a cancer type using the silhouette score and found that the detected subtypes exhibit significant differences in survival profiles. Furthermore, we compared the effect of feature selection and similarity measures for subtype detection. For further evaluation, we used the Glioblastoma multiforme (GBM) dataset and identified the differentially expressed genes in each of the subtypes. The results obtained are consistent with other genomic studies and can be corroborated with the involved pathways and biological functions. Thus, it shows that the results from the autoencoders, obtained through the interaction of different datatypes of cancer, can be used for the prediction and characterization of patient subgroups and survival profiles.


2017 ◽  
Vol 166 (1) ◽  
pp. 195-195 ◽  
Author(s):  
María Elena Martínez ◽  
Scarlett L. Gomez ◽  
Li Tao ◽  
Rosemary Cress ◽  
Danielle Rodriguez ◽  
...  

2020 ◽  
Author(s):  
Zhuoran Xu ◽  
Akanksha Verma ◽  
Uska Naveed ◽  
Samuel Bakhoum ◽  
Pegah Khosravi ◽  
...  

Chromosomal instability (CIN) is a hallmark of human cancer that involves mis-segregation of chromosomes during mitosis, leading to aneuploidy and genomic copy number heterogeneity. CIN is a prognostic marker in a variety of cancers, yet, gold-standard experimental assessment of chromosome mis-segregation is difficult in the routine clinical setting. As a result, CIN status is not readily testable for cancer patients in such setting. On the other hand, the gold-standard for cancer diagnosis and grading, histopathological examinations, are ubiquitously available. In this study, we sought to explore whether CIN status can be predicted using hematoxylin and eosin (H&E) histology in breast cancer patients. Specifically, we examined whether CIN, defined using a genomic aneuploidy burden approach, can be predicted using a deep learning-based model. We applied transfer learning on convolutional neural network (CNN) models to extract histological features and trained a multilayer perceptron (MLP) after aggregating patch features obtained from whole slide images. When applied to a breast cancer cohort of 1,010 patients (Training set: n=858 patients, Test set: n=152 patients) from The Cancer Genome Atlas (TCGA) where 485 patients have high CIN status, our model accurately classified CIN status, achieving an area under the curve (AUC) of 0.822 with 81.2% sensitivity and 68.7% specificity in the test set. Patch-level predictions of CIN status suggested intra-tumor spatial heterogeneity within slides. Moreover, presence of patches with high predicted CIN score within an entire slide was more predictive of clinical outcome than the average CIN score of the slide, thus underscoring the clinical importance of spatial heterogeneity. Overall, we demonstrated the ability of deep learning methods to predict CIN status based on histopathology slide images. Our model is not breast cancer subtype specific and the method can be potentially extended to other cancer types.


2010 ◽  
Vol 1 (5) ◽  
pp. 747-754 ◽  
Author(s):  
REIKI NISHIMURA ◽  
TOMOFUMI OSAKO ◽  
YASUHIRO OKUMURA ◽  
MITSUHIRO HAYASHI ◽  
YASUO TOYOZUMI ◽  
...  

2021 ◽  
Vol 11 (5) ◽  
pp. 392-400
Author(s):  
Fajar Lamhot Gultom ◽  
Marliana Nurprilinda ◽  
Ryani Nur Cahyaning Hutami

Immunohistochemistry examination (IHC) is one of the additional tests to diagnose and determine breast cancer subtype. IHC examination is a method to check intracellular protein using a monoclonal and polyclonal antibody to detect the antigen in tissue. IHC examination determined by hormone receptor markers (ER and PR), HER-2/Neu expression, and apoptotic and proliferation markers (Ki-67 and p53) can be used to determine therapy and prognosis. This study aims to determine the hormonal status of breast cancer patient at Siloam Semanggi Hospital in 2018, in the form of age, gender, pathology diagnose, and the result of IHC (ER, PR, HER2, and Ki-67). This study is a retrospective descriptive study using pathological anatomy laboratory results of breast cancer in MRCCC Siloam Semanggi Hospital and 208 patients following inclusion and exclusion criteria. The result obtained is that the age group with the highest frequency is 50-59 years, with 34.1%. The highest frequency by gender is a woman with 99.5%. Carcinoma mammae NST with grade II and III was found in 38.0% of patients. The hormonal receptor with ER and PR positive was found in 51.0% of patients. HER2 expression negative was found in 56.7% of patients. High proliferation Ki-67 was found in 82.7% of patients. Luminal B with HER2 negative subtype was found in 32.2% of patients. Patients in 50-59 years with Luminal B with HER2 negative subtype was found in 26 patients. Patients in carcinoma mammae NST with grade II with Luminal B with HER2 negative subtype was found in 27 patients. Keywords: Breast cancer, pathologic anatomy, immunohistochemistry, breast cancer subtype


Sign in / Sign up

Export Citation Format

Share Document